Peptide News Digest

#Liver

2 stories

Research · View digest

Cell Metabolism: Semaglutide's Liver Benefits in MASH Driven by Sinusoidal Endothelial Cell Receptors, Independent of Weight Loss

Researchers at Toronto's Sinai Health published in Cell Metabolism that semaglutide acts directly on liver sinusoidal endothelial cells (LSECs) to reverse MASH independently of weight loss. Although LSECs account for only ~3% of liver cell volume, they are the key driver of hepatoprotection. Semaglutide reversed MASH in mice lacking brain appetite receptors, while mice lacking LSEC receptors saw no liver improvement despite losing 20% body weight.

Regulatory · View digest

FDA Requests Post-Market Liver Injury and Cardiovascular Safety Data on Foundayo

The FDA asked Eli Lilly for additional safety data on liver injury linked to Foundayo (orforglipron), plus post-marketing trials to assess cardiovascular event risk and delayed gastric emptying. A lactation study was also required. The letter, signed April 1, was published April 14 — just two weeks after the drug's fast-track approval under the National Priority Voucher program.